Home

U.S. Food and Drug Administration Approves Viread® for Chronic Hepatitis B in Adults

Important New Treatment Option for Millions in United States Affected by Life-Threatening Liver Disease

Learn More

News

Read Gilead's 2007 Annual Report
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3
U.S. Food and Drug Administration Approves Viread(R) for Chronic Hepatitis B in Adults
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries
View all news

Events

September 3 - 5, 2008
Thomas Weisel Partners 2008 Healthcare Conference
Boston, MA
Listen to Webcast
September 16 - 18, 2008
Merrill Lynch Global Pharmaceutical Conference 2008
London, UK
September 18 - 21, 2008
The United States Conference on AIDS
Miami, FL
View all events

Corporate Responsibility

We are committed to improving the communities in which we live and serve. Our commitment extends beyond the products we offer by demonstrating our compassion and dedication to improving the health of individuals around the world.
Learn more

Gilead Careers and Culture

Our greatest asset is our employees – not only their individual skills, expertise and vision, but their inspired personal commitment to our mission of making a difference in the lives of patients suffering from serious unmet medical needs.
Learn more

Gilead Worldwide

Today, we have more than 3,200 employees and operations in North America and several countries throughout Europe and Australia.
Learn more

Products and Clinical Research